TIDMCTEC
RNS Number : 9695X
ConvaTec Group PLC
07 May 2021
ConvaTec Group Plc
Results of Annual General Meeting
Reading, United Kingdom 7 May 2021 - Poll Result
ConvaTec Group Plc ("ConvaTec") held its annual general meeting
today ("AGM"). The results of the poll held in relation to the
resolutions proposed at the AGM are set out below:
For Against Total Votes % of Number
(see note 2) (see note 2) cast ISC Voted of Votes
Withheld
(see note
3)
Resolution No of shares % No of shares %
-------------- ------- ------------- -----
Receive Annual
Report and
1 Accounts 1,744,608,352 99.96 777,616 0.04 1,745,385,968 87.08% 1,480,001
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Approve the
Directors'
Remuneration
2 Report 1,698,130,077 97.23 48,413,492 2.77 1,746,543,569 87.14% 322,400
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Declare Final
3 Dividend 1,740,839,314 99.66 5,915,934 0.34 1,746,755,248 87.15% 110,721
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect John
McAdam as a
4 director 1,726,805,777 98.88 19,520,971 1.12 1,746,326,748 87.13% 539,221
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Karim
Bitar as a
5 director 1,745,847,330 99.95 907,151 0.05 1,746,754,481 87.15% 111,488
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Frank
Schulkes as
6 a director 1,739,573,569 99.59 7,176,168 0.41 1,746,749,737 87.15% 116,232
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Margaret
Ewing as a
7 director 1,735,171,507 99.34 11,573,127 0.66 1,746,744,634 87.15% 121,335
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Brian
8 May as a director 1,726,852,048 98.86 19,898,392 1.14 1,746,750,440 87.15% 115,529
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Rick
Anderson as
9 a director 1,732,922,453 99.21 13,822,181 0.79 1,746,744,634 87.15% 121,335
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Regina
Benjamin as
10 a director 1,733,824,898 99.26 12,925,036 0.74 1,746,749,934 87.15% 116,035
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-elect Sten
Scheibye as
11 a director 1,745,567,146 99.93 1,187,335 0.07 1,746,754,481 87.15% 111,488
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Elect Heather
Mason as a
12 director 1,744,886,278 99.89 1,863,459 0.11 1,746,749,737 87.15% 116,232
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Elect Constantin
Coussios as
13 a director 1,744,393,943 99.87 2,356,497 0.13 1,746,750,440 87.15% 115,529
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Re-appoint
Deloitte LLP
14 as auditor 1,746,633,262 99.99 118,345 0.01 1,746,751,607 87.15% 114,362
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Authorise the
directors to
determine the
remuneration
of the Company's
15 auditor 1,746,753,488 100.00 433 0.00 1,746,753,921 87.15% 112,048
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Authorise political
donations and
16 political expenditure 1,721,717,493 98.58 24,812,022 1.42 1,746,529,515 87.14% 336,454
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Authorise allotment
17 of shares 1,623,589,106 92.97 122,709,426 7.03 1,746,298,532 87.13% 567,437
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Disapply pre-emption
18 rights* 1,736,680,253 99.45 9,522,182 0.55 1,746,202,435 87.12% 663,534
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Disapply pre-emption
rights in connection
with an acquisition
or specified
19 capital investment* 1,691,979,685 96.87 54,580,936 3.13 1,746,560,621 87.14% 305,348
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Authorise purchase
20 of own shares* 1,741,411,621 99.75 4,350,959 0.25 1,745,762,580 87.10% 1,103,389
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
Call general
meetings on
21 14 days' notice* 1,657,330,730 94.88 89,418,003 5.12 1,746,748,733 87.15% 117,236
----------------------- -------------- ------- ------------- ----- -------------- ----------- -----------
*Special Resolution
NOTES:
1. All resolutions were passed.
2. Votes "For" and "Against" are expressed as a percentage of votes received.
3. A "Vote withheld" is not a vote in law and is not counted in
the calculation of the votes "For" or "Against" a resolution.
4. Total number of shares in issue at close of business on 5 May
2021 was 2,004,347,138 shares; 87.15% of voting capital was
instructed.
5. Computershare acted as scrutineer of the poll on all resolutions.
In accordance with Listing Rule 9.6.2, copies of the resolutions
that do not constitute ordinary business that were passed at the
Meeting will be submitted to the National Storage Mechanism and
will be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism .
About ConvaTec
ConvaTec is a global medical products and technologies company
focused on therapies for the management of chronic conditions, with
leading market positions in advanced wound care, ostomy care,
continence and critical care, and infusion care. Our vision, which
encompasses our purpose, is: Pioneering trusted medical solutions
to improve the lives we touch. Our products provide a range of
clinical and economic benefits including infection prevention,
protection of at-risk skin, improved patient outcomes and reduced
total cost of care. To learn more about ConvaTec, please visit
www.convatecgroup.com
Enquiries
Analysts and Investors
Kate Postans, Vice President Investor Relations, ConvaTec +44 (0)7826 447 807
ir@convatec.com
Media
Buchanan: Charles Ryland / Chris Lane +44 (0)207 466 5000
ConvaTec Group Plc's LEI code is 213800LS272L4FIDOH92
# # #
END
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RAGUBSORAOUVRAR
(END) Dow Jones Newswires
May 07, 2021 09:50 ET (13:50 GMT)
Convatec (LSE:CTEC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Convatec (LSE:CTEC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024